Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 382-395

  Henderson, Paul ^a,b,c   Van Limbergen, Johan E ^d   Schwarze, Jürgen ^a,c   Wilson, David C ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

enterocytes; epithelial cells; inflammatory bowel diseases; mucosal immunology

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR9; IMMUNOGLOBULIN A; INTERLEUKIN 10; INTERLEUKIN 22; INTERLEUKIN 31;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CELL STRUCTURE; CROHN DISEASE; HUMAN; IMMUNOCOMPETENT CELL; INTESTINE CELL; INTESTINE EPITHELIUM; INTESTINE FUNCTION; PINOCYTOSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; ULCERATIVE COLITIS;

HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL ABSORPTION; INTESTINAL MUCOSA;

EID: 78650085568     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21379     Document Type: Review

References (209)

1. Henderson P, Van Limbergen J, Wilson DC, et al. Genetics of childhood-onset inflammatory bowel disease. Inflamm Bowel Dis. 2010; Apr 19. [Epub ahead of print].
2. McGuckin MA, Eri R, Simms LA, et al. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2009; 15: 100-113.
3. Dotan I, Allez M, Nakazawa A, et al. Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma. Am J Physiol Gastrointest Liver Physiol. 2007; 292: G1630-1640.
4. De Benedetto A, Qualia CM, Baroody FM, et al. Filaggrin expression in oral, nasal, and esophageal mucosa. J Invest Dermatol. 2008; 128: 1594-1597.
5. Van Limbergen J, Russell RK, Nimmo ER, et al. Filaggrin loss-of-function variants are associated with atopic comorbidity in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 1492-1498.
6. van der Flier LG, Clevers H,. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol. 2009; 71: 241-260.
7. Simon-Assmann P, Turck N, Sidhoum-Jenny M, et al. In vitro models of intestinal epithelial cell differentiation. Cell Biol Toxicol. 2007; 23: 241-256.
8. Ramasundara M, Leach ST, Lemberg DA, et al. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol. 2009; 24: 202-208.
9. Snoeck V, Goddeeris B, Cox E,. The role of enterocytes in the intestinal barrier function and antigen uptake. Microbes Infect. 2005; 7: 997-1004.
10. Kyd JM, Cripps AW,. Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine. 2008; 26: 6221-6224.
11. Kraehenbuhl JP, Neutra MR,. Epithelial M cells: differentiation and function. Annu Rev Cell Dev Biol. 2000; 16: 301-332.
12. Knoop KA, Kumar N, Butler BR, et al. RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol. 2009; 183: 5738-5747.
13. Lo D, Tynan W, Dickerson J, et al. Cell culture modeling of specialized tissue: identification of genes expressed specifically by follicle-associated epithelium of Peyer's patch by expression profiling of Caco-2/Raji co-cultures. Int Immunol. 2004; 16: 91-99.
14. Ismail AS, Behrendt CL, Hooper LV,. Reciprocal interactions between commensal bacteria and gamma delta intraepithelial lymphocytes during mucosal injury. J Immunol. 2009; 182: 3047-3054.
15. Hayday A, Theodoridis E, Ramsburg E, et al. Intraepithelial lymphocytes: exploring the Third Way in immunology. Nat Immunol. 2001; 2: 997-1003.
16. Beagley KW, Fujihashi K, Lagoo AS, et al. Differences in intraepithelial lymphocyte T cell subsets isolated from murine small versus large intestine. J Immunol. 1995; 154: 5611-5619.
17. Camerini V, Panwala C, Kronenberg M,. Regional specialization of the mucosal immune system. Intraepithelial lymphocytes of the large intestine have a different phenotype and function than those of the small intestine. J Immunol. 1993; 151: 1765-1776.
18. Jabri B, Ebert E,. Human CD8+ intraepithelial lymphocytes: a unique model to study the regulation of effector cytotoxic T lymphocytes in tissue. Immunol Rev. 2007; 215: 202-214.
19. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999; 285: 727-729.
20. Allez M, Tieng V, Nakazawa A, et al. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology. 2007; 132: 2346-2358.
21. Kinoshita N, Hiroi T, Ohta N, et al. Autocrine IL-15 Mediates intestinal epithelial cell death via the activation of neighboring intraepithelial NK cells. J Immunol. 2002; 169: 6187-6192.
22. Shinozaki M, Hirahashi J, Lebedeva T, et al. IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J Clin Invest. 2002; 109: 951-960.
23. Obermeier F, Hausmann M, Kellermeier S, et al. IL-15 protects intestinal epithelial cells. Eur J Immunol. 2006; 36: 2691-2699.
24. Heap GA, van Heel DA,. The genetics of chronic inflammatory diseases. Hum Mol Genet. 2009; 18: R101-106.
25. Bernardo D, Garrote JA, Allegretti Y, et al. Higher constitutive IL15R alpha expression and lower IL-15 response threshold in coeliac disease patients. Clin Exp Immunol. 2008; 154: 64-73.
26. Kunisawa J, Takahashi I, Kiyono H,. Intraepithelial lymphocytes: their shared and divergent immunological behaviors in the small and large intestine. Immunol Rev. 2007; 215: 136-153.
27. Johansson-Lindbom B, Agace WW,. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Rev. 2007; 215: 226-242.
28. Wurbel MA, Malissen M, Guy-Grand D, et al. Impaired accumulation of antigen-specific CD8 lymphocytes in chemokine CCL25-deficient intestinal epithelium and lamina propria. J Immunol. 2007; 178: 7598-7606.
29. Papadakis KA, Prehn J, Moreno ST, et al. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology. 2001; 121: 246-254.
30. Saruta M, Yu QT, Avanesyan A, et al. Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J Immunol. 2007; 178: 3293-3300.
31. Agace WW, Higgins JM, Sadasivan B, et al. T-lymphocyte-epithelial-cell interactions: integrin alpha(E)(CD103)beta(7), LEEP-CAM and chemokines. Curr Opin Cell Biol. 2000; 12: 563-568.
32. Apostolaki M, Manoloukos M, Roulis M, et al. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology. 2008; 134: 2025-2035.
33. Souza HS, Elia CC, Spencer J, et al. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999; 45: 856-863.
34. Picarella D, Hurlbut P, Rottman J, et al. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol. 1997; 158: 2099-2106.
35. Staton TL, Habtezion A, Winslow MM, et al. CD8+ recent thymic emigrants home to and efficiently repopulate the small intestine epithelium. Nat Immunol. 2006; 7: 482-488.
36. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med. 2005; 352: 2499-2507.
37. Keshav S, Ungasher S, Zheng W, et al. CCX282-B, an orally active inhibitor of chemokine receptor CCR9, shows anti-infl ammatory & clinical activity in the treatment of Crohn's disease. Gastroenterology. 2007; 132 (Suppl): A157.
38. Hossain Z, Hirata T,. Molecular mechanism of intestinal permeability: interaction at tight junctions. Mol BioSyst. 2008; 4: 1181-1185.
39. Schulzke JD, Gitter AH, Mankertz J, et al. Epithelial transport and barrier function in occludin-deficient mice. Biochim Biophys Acta. 2005; 1669: 34-42.
40. Park JY, Park KH, Oh TY, et al. Up-regulated claudin 7 expression in intestinal-type gastric carcinoma. Oncol Rep. 2007; 18: 377-382.
41. Muise AM, Walters TD, Glowacka WK, et al. Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn's disease. Gut. 2009; 58: 1121-1127.
42. Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell, 5th ed. New York: Garland Science; 2007.
43. Miele E, Pascarella F, Quaglietta L, et al. Altered intestinal permeability is predictive of early relapse in children with steroid-responsive ulcerative colitis. Aliment Pharmacol Ther. 2007; 25: 933-939.
44. Clayburgh DR, Shen L, Turner JR,. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest. 2004; 84: 282-291.
45. Secondulfo M, de Magistris L, Fiandra R, et al. Intestinal permeability in Crohn's disease patients and their first degree relatives. Dig Liver Dis. 2001; 33: 680-685.
46. Soderholm JD, Olaison G, Lindberg E, et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? Gut. 1999; 44: 96-100.
47. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet. 1993; 341: 1437-1439.
48. Porras M, Martin MT, Yang PC, et al. Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation. Inflamm Bowel Dis. 2006; 12: 843-852.
49. Buhner S, Buning C, Genschel J, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut. 2006; 55: 342-347.
50. Demetter P, De Vos M, Van Damme N, et al. Focal up-regulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated cell lineage. Am J Clin Pathol. 2000; 114: 364-370.
51. Sasaki M, Sitaraman SV, Babbin BA, et al. Invasive Escherichia coli are a feature of Crohn's disease. Lab Invest. 2007; 87: 1042-1054.
52. McGovern DP, Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010; 42: 332-337.
53. Vetrano S, Rescigno M, Cera MR, et al. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology. 2008; 135: 173-184.
54. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008; 40: 955-962.
55. Scharl M, Paul G, Weber A, et al. Protection of epithelial barrier function by the Crohn's disease associated gene protein tyrosine phosphatase N2. Gastroenterology. 2009; 137: 2030-2040.
56. Hassan SW, Doody KM, Hardy S, et al. Increased susceptibility to dextran sulfate sodium induced colitis in the T cell protein tyrosine phosphatase heterozygous mouse. PLoS One. 2010; 5: e8868.
57. Kucharzik T, Walsh SV, Chen J, et al. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol. 2001; 159: 2001-2009.
58. Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007; 56: 61-72.
59. Zolotarevsky Y, Hecht G, Koutsouris A, et al. A membrane-permanent peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology. 2002; 123: 163-172.
60. Ye D, Ma I, Ma TY,. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G496-504.
61. Groschwitz KR, Hogan SP,. Intestinal barrier function: Molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009; 124: 3-20.
62. Gaudier E, Hoebler C,. Physiological role of mucins in the colonic barrier integrity. Gastroenterol Clin Biol. 2006; 30: 965-974.
63. Dahan S, Roth-Walter F, Arnaboldi P, et al. Epithelia: lymphocyte interactions in the gut. Immunol Rev. 2007; 215: 243-253.
64. Camp JG, Kanther M, Semova I, et al. Patterns and scales in gastrointestinal microbial ecology. Gastroenterology. 2009; 136: 1989-2002.
65. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464: 59-65.
66. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599-603.
67. Kelsall B,. Getting to the guts of NOD2. Nat Med. 2005; 11: 383-384.
68. Petnicki-Ocwieja T, Hrncir T, Liu YJ, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA. 2009; 106: 15813-15818.
69. Browning BL, Huebner C, Petermann I, et al. Has Toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol. 2007; 102: 2504-2512.
70. Hume GE, Fowler EV, Doecke J, et al. Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn's disease in an Australian population. Inflamm Bowel Dis. 2008; 14: 585-590.
71. Labbe C, Goyette P, Lefebvre C, et al. MAST3: a novel IBD risk factor that modulates TLR4 signaling. Genes Immun. 2008; 9: 602-612.
72. Cario E, Podolsky DK,. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000; 68: 7010-7017.
73. Otte J-M, Cario E, Podolsky DK,. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology. 2004; 126: 1054-1070.
74. Gribar SC, Anand RJ, Sodhi CP, et al. The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol. 2008; 83: 493-498.
75. Torok HP, Glas J, Tonenchi L, et al. Crohn's disease is associated with a Toll-like receptor-9 polymorphism. Gastroenterology. 2004; 127: 365-366.
76. Hong J, Leung E, Fraser AG, et al. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol. 2007; 22: 1760-1766. (Pubitemid 47525075)
77. Sanchez-Munoz F, Fonseca-Camarillo GC, Villeda-Ramirez MA, et al. TLR9 mRNA expression is upregulated in patients with active ulcerative colitis. Inflamm Bowel Dis. 2009 [Epub ahead of print].
78. Zhernakova A, Festen EM, Franke L, et al. Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet. 2008; 82: 1202-1210.
79. Hsu YM, Zhang Y, You Y, et al. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol. 2007; 8: 198-205.
80. LeibundGut-Landmann S, Gross O, Robinson MJ, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol. 2007; 8: 630-638.
81. Poeck H, Bscheider M, Gross O, et al. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol. 2010; 11: 63-69.
82. Niess JH,. Role of mucosal dendritic cells in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 5138-5148.
83. Shale M, Ghosh S,. How intestinal epithelial cells tolerise dendritic cells and its relevance to inflammatory bowel disease. Gut. 2009; 58: 1291-1299.
84. Iliev ID, Matteoli G, Rescigno M,. The yin and yang of intestinal epithelial cells in controlling dendritic cell function. J Exp Med. 2007; 204: 2253-2257.
85. Sun C-M, Hall JA, Blank RB, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med. 2007; 204: 1775-1785.
86. Uematsu S, Fujimoto K, Jang MH, et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol. 2008; 9: 769-776.
87. Mora JR, Iwata M, Eksteen B, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science. 2006; 314: 1157-1160.
88. Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature. 2003; 424: 88-93.
89. Yoshida M, Claypool SM, Wagner JS, et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity. 2004; 20: 769-783.
90. Huang FP, Platt N, Wykes M, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med. 2000; 191: 435-444.
91. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001; 2: 361-367.
92. Iliev ID, Spadoni I, Mileti E, et al. Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut. 2009: 175-176.
93. Siddiqui KR, Laffont S, Powrie F,. E-cadherin marks a subset of inflammatory dendritic cells that promote T cell-mediated colitis. Immunity. 2010; 32: 557-567.
94. Cai Z, Zhang W, Li M, et al. TGF-beta1 gene-modified, immature dendritic cells delay the development of inflammatory bowel disease by inducing CD4(+)Foxp3(+) regulatory T cells. Cell Mol Immunol. 2010; 7: 35-43.
95. Kwon HK, Lee CG, So JS, et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci USA. 2010; 107: 2159-2164.
96. Zaph C, Troy AE, Taylor BC, et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature. 2007; 446: 552-556.
97. Rimoldi M, Chieppa M, Salucci V, et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol. 2005; 6: 507-514.
98. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005; 129: 50-65.
99. Blumberg RS, Lencer WI, Zhu X, et al. Antigen presentation by intestinal epithelial cells. Immunol Lett. 1999; 69: 7-11.
100. Lu L, Khan S, Lencer W, et al. Endocytosis of cholera toxin by human enterocytes is developmentally regulated. Am J Physiol Gastrointest Liver Physiol. 2005; 289: G332-341.
101. Laiping So A, Pelton-Henrion K, Small G, et al. Antigen uptake and trafficking in human intestinal epithelial cells. Dig Dis Sci. 2000; 45: 1451-1461. (Pubitemid 30636525)
102. Baker K, Qiao SW, Kuo T, et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol. 2009; 31: 223-236.
103. Kobayashi K, Qiao SW, Yoshida M, et al. An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology. 2009; 137: 1746-1756.
104. Yu LC, Yang PC, Berin MC, et al. Enhanced transepithelial antigen transport in intestine of allergic mice is mediated by IgE/CD23 and regulated by interleukin-4. Gastroenterology. 2001; 121: 370-381.
105. Kaiserlian D, Lachaux A, Grosjean I, et al. Intestinal epithelial cells express the CD23/Fc epsilon RII molecule: enhanced expression in enteropathies. Immunology. 1993; 80: 90-95.
106. Tello-Ruiz MK, Curley C, DelMonte T, et al. Haplotype-based association analysis of 56 functional candidate genes in the IBD6 locus on chromosome 19. Eur J Hum Genet. 2006; 14: 780-790.
107. Asano K, Matsushita T, Umeno J, et al. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet. 2009; 41: 1325-1329.
108. Hershberg RM, Framson PE, Cho DH, et al. Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing. J Clin Invest. 1997; 100: 204-215.
109. Hundorfean G, Zimmer KP, Strobel S, et al. Luminal antigens access late endosomes of intestinal epithelial cells enriched in MHC I and MHC II molecules: in vivo study in Crohn's ileitis. Am J Physiol Gastrointest Liver Physiol. 2007; 293: G798-808.
110. Buning J, von Smolinski D, Tafazzoli K, et al. Multivesicular bodies in intestinal epithelial cells: responsible for MHC class II-restricted antigen processing and origin of exosomes. Immunology. 2008; 125: 510-521.
111. Soderholm JD, Streutker C, Yang PC, et al. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut. 2004; 53: 1817-1824.
112. Kersting S, Bruewer M, Schuermann G, et al. Antigen transport and cytoskeletal characteristics of a distinct enterocyte population in inflammatory bowel diseases. Am J Pathol. 2004; 165: 425-437.
113. Cadwell K, Liu JY, Brown SL, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature. 2008; 456: 259-263.
114. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007; 39: 207-211. (Pubitemid 46184351)
115. Kuballa P, Huett A, Rioux JD, et al. Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS One. 2008; 3: e3391.
116. Lapaquette P, Glasser AL, Huett A, et al. Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol. 2010; 12: 99-113.
117. Feng CG, Zheng L, Jankovic D, et al. The immunity-related GTPase Irgm1 promotes the expansion of activated CD4+ T cell populations by preventing interferon-gamma-induced cell death. Nat Immunol. 2008; 9: 1279-1287.
118. Henry SC, Traver M, Daniell X, et al. Regulation of macrophage motility by Irgm1. J Leukoc Biol. 2009; 87: 333-343.
119. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010; 16: 90-97.
120. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol. 2010; 11: 55-62.
121. Visekruna A, Joeris T, Schmidt N, et al. Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues: The proteasome pattern as diagnostic tool for IBD patients. Inflamm Bowel Dis. 2009; 15: 526-533.
122. Bland P,. MHC class II expression by the gut epithelium. Immunol Today. 1988; 9: 174-178.
123. Shao L, Kamalu O, Mayer L,. Non-classical MHC class I molecules on intestinal epithelial cells: mediators of mucosal crosstalk. Immunol Rev. 2005; 206: 160-176.
124. Perera L, Shao L, Patel A, et al. Expression of nonclassical class I molecules by intestinal epithelial cells. Inflamm Bowel Dis. 2007; 13: 298-307.
125. Lu M, Xia B, Ge L, et al. Role of major histocompatibility complex class I-related molecules A*A5.1 allele in ulcerative colitis in Chinese patients. Immunology. 2009; 128 (1 Suppl): e230-236.
126. Aldemir H,. Novel MHC class I-related molecule MR1 affects MHC class I expression in 293T cells. Biochem Biophys Res Commun. 2008; 366: 328-334.
127. Nieuwenhuis EES, Matsumoto T, Lindenbergh D, et al. Cd1d-dependent regulation of bacterial colonization in the intestine of mice. J Clin Invest. 2009; 119: 1241-1250.
128. Mallegol J, van Niel G, Heyman M, et al. Phenotypic and functional characterization of intestinal epithelial exosomes. Blood Cells Mol Dis. 2005; 35: 11-16.
129. Lin XP, Almqvist N, Telemo E,. Human small intestinal epithelial cells constitutively express the key elements for antigen processing and the production of exosomes. Blood Cells Mol Dis. 2005; 35: 122-128.
130. Wehkamp J, Schmid M, Stange EF,. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol. 2007; 23: 370-378.
131. Fellermann K, Wehkamp J, Herrlinger KR, et al. Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol. 2003; 15: 627-634.
132. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA. 2005; 102: 18129-18134.
133. Perminow G, Beisner J, Koslowski M, et al. Defective paneth cell-mediated host defense in pediatric ileal Crohn's disease. Am J Gastroenterol. 2010; 105: 452-459.
134. Schauber JAD, Rieger DA, Weiler FA, et al. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2006; 18: 615-621.
135. Saba K, Denda-Nagai K, Irimura T,. A C-type lectin MGL1/CD301a plays an anti-inflammatory role in murine experimental colitis. Am J Pathol. 2009; 174: 144-152.
136. Marquez A, Varade J, Robledo G, et al. Specific association of a CLEC16A/KIAA0350 polymorphism with NOD2/CARD15(-) Crohn's disease patients. Eur J Hum Genet. 2009; 17: 1304-1308.
137. Cerutti A, Rescigno M,. The biology of intestinal immunoglobulin A responses. Immunity. 2008; 28: 740-750.
138. Mostov KE, Deitcher DL,. Polymeric immunoglobulin receptor expressed in MDCK cells transcytoses IgA. Cell. 1986; 46: 613-621.
139. Peterson DA, McNulty NP, Guruge JL, et al. IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe. 2007; 2: 328-339.
140. Kadaoui KA, Corthesy B,. Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. J Immunol. 2007; 179: 7751-7757.
141. Pasquier B, Launay P, Kanamaru Y, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity. 2005; 22: 31-42.
142. Murthy AK, Dubose CN, Banas JA, et al. Contribution of polymeric immunoglobulin receptor to regulation of intestinal inflammation in dextran sulfate sodium-induced colitis. J Gastroenterol Hepatol. 2006; 21: 1372-1380.
143. van der Steen L, Tuk CW, Bakema JE, et al. Immunoglobulin A: FcalphaRI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology. 2009; 137: 2018-2029.
144. Rutgeerts P, Vermeire S, Van Assche G,. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009; 136: 1182-1197.
145. Yun L, Hanauer S,. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009; 3: 235-248.
146. Yeckes AR, Hoffenberg EJ,. Rapid infliximab infusions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009; 49: 151-154.
147. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117: 761-769.
148. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008; 135: 1130-1141.
149. Akobeng AK, Zachos M,. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2004: CD003574.
150. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132: 863-873.
151. Ruemmele FM, Lachaux A, Cezard JP, et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis. 2009; 15: 388-394.
152. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000; 408: 57-63.
153. Collins M, Whitters M, Young D,. IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity. Immunol Res. 2003; 28: 131-140.
154. Caruso R, Fina D, Peluso I, et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology. 2007; 132: 166-175.
155. Leonard WJ, Spolski R,. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol. 2005; 5: 688-698.
156. Fina D, Sarra M, Fantini MC, et al. Regulation of gut inflammation and Th17 cell response by interleukin-21. Gastroenterology. 2008; 134: 1038-1048.
157. Fantini MC, Monteleone G, MacDonald TT,. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 1419-1423.
158. Dumoutier L, Van Roost E, Colau D, et al. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci USA. 2000; 97: 10144-10149.
159. Aggarwal S, Xie M-H, Maruoka M, et al. Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res. 2001; 21: 1047.
160. Wolk K, Haugen H, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not. J Mol Med. 2009; 87: 523-536.
161. Nagalakshmi ML, Rascle A, Zurawski S, et al. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol. 2004; 4: 679-691.
162. Chambers RE, Stross P, Barry RE, et al. Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest. 1987; 17: 460-467.
163. Humberto BJ, Karen LM, John WW, et al. Serum amyloid A activates NF-kB and proinflammatory gene expression in human and murine intestinal epithelial cells. Eur J Immunol. 2005; 35: 718-726.
164. Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G827-838.
165. Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004; 5: 752-760.
166. Zhang Q, Putheti P, Zhou Q, et al. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008; 19: 347-356.
167. Dambacher J, Beigel F, Seiderer J, et al. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut. 2007; 56: 1257-1265.
168. Brand S, Olszak T, Beigel F, et al. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem. 2006; 97: 709-723.
169. Kim S-H, Han S-Y, Azam T, et al. Interleukin-32: a cytokine and inducer of TNF alpha. Immunity. 2005; 22: 131-142.
170. Netea MG, Azam T, Ferwerda G, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1a and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA. 2005; 102: 16309-314.
171. Shioya M, Nishida A, Yagi Y, et al. Epithelial overexpression of interleukin-32α in inflammatory bowel disease. Clin Exp Immunol. 2007; 149: 480-486.
172. Zimmerman NP, Vongsa RA, Wendt MK, et al. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1000-1011.
173. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000; 52: 145-176.
174. Heidemann J, Ogawa H, Rafiee P, et al. Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells. Am J Physiol Gastrointest Liver Physiol. 2004; 286: G1059-1068.
175. Janas ML, Varano G, Gudmundsson K, et al. Thymic development beyond beta-selection requires phosphatidylinositol 3-kinase activation by CXCR4. J Exp Med. 2010; 207: 247-261.
176. Moyer RA, Wendt MK, Johanesen PA, et al. Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia. Lab Invest. 2007; 87: 807-817.
177. Banks C, Bateman A, Payne R, et al. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol. 2003; 199: 28-35.
178. Lee HJ, Choi SC, Lee MH, et al. Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down-regulation by sulfasalazine and glucocorticoid treatment. Inflamm Bowel Dis. 2005; 11: 1070-1079.
179. Grip O, Janciauskiene S,. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One. 2009; 4: e5263.
180. Kotarsky K, Sitnik KM, Stenstad H, et al. A novel role for constitutively expressed epithelial-derived chemokines as antibacterial peptides in the intestinal mucosa. Mucosal Immunol. 2010; 3: 40-48.
181. Dotan I, Werner L, Vigodman S, et al. CXCL12 Is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm Bowel Dis. 2009; 16: 583-592.
182. Lazarus NH, Kunkel EJ, Johnston B, et al. A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA
183. Christ AD, Colgan SP, Balk SP, et al. Human intestinal epithelial cell lines produce factor(s) that inhibit CD3-mediated T-lymphocyte proliferation. Immunol Lett. 1997; 58: 159-165.
184. Cruickshank SM, McVay LD, Baumgart DC, et al. Colonic epithelial cell mediated suppression of CD4 T cell activation. Gut. 2004; 53: 678-684.
185. Li XC, Almawi W, Jevnikar A, et al. Allogeneic lymphocyte proliferation stimulated by small intestine-derived epithelial cells. Transplantation. 1995; 60: 82-89.
186. Hoang P, Crotty B, Dalton HR, et al. Epithelial cells bearing class II molecules stimulate allogeneic human colonic intraepithelial lymphocytes. Gut. 1992; 33: 1089-1093.
187. Panja A, Barone A, Mayer L,. Stimulation of lamina propria lymphocytes by intestinal epithelial cells: evidence for recognition of nonclassical restriction elements. J Exp Med. 1994; 179: 943-950.
188. Joseph NE, Fiocchi C, Levine AD,. Crohn's disease and ulcerative colitis mucosal T cells are stimulated by intestinal epithelial cells: implications for immunosuppressive therapy. Surgery. 1997; 122: 809-814. Discussion 814-816.
189. Nakazawa A, Dotan I, Brimnes J, et al. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology. 2004; 126: 1347-1357.
190. Imielinski M, Baldassano RN, Griffiths A, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet. 2009; 41: 1335-1340.
191. Wang K, Baldassano R, Zhang H, et al. Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. Hum Mol Genet. 2010 [Epub ahead of print].
192. Palmer MT, Weaver CT,. Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat Immunol. 2010; 11: 36-40.
193. Brand S,. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009; 58: 1152-1167.
194. Mayer L, Eisenhardt D,. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest. 1990; 86: 1255-1260.
195. Wing K, Sakaguchi S,. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010; 11: 7-13.
196. Tsuji NM, Kosaka A,. Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol. 2008; 29: 532-540.
197. Tsuji NM,. Antigen-specific CD4(+) regulatory T cells in the intestine. Inflamm Allergy Drug Targets. 2006; 5: 191-201.
198. Izcue A, Coombes JL, Powrie F,. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol. 2009; 27: 313-338.
199. Boden EK, Snapper SB,. Regulatory T cells in inflammatory bowel disease. Curr Opin Gastroenterol. 2008; 24: 733-741.
200. Westendorf AM, Fleissner D, Groebe L, et al. CD4+Foxp3+ regulatory T cell expansion induced by antigen-driven interaction with intestinal epithelial cells independent of local dendritic cells. Gut. 2009; 58: 211-219.
201. Allez M, Brimnes J, Dotan I, et al. Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology. 2002; 123: 1516-1526.
202. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993; 75: 263-274.
203. Wirtz S, Neurath MF,. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev. 2007; 59: 1073-1083.
204. Noguchi E, Homma Y, Kang X, et al. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol. 2009; 10: 471-479.
205. Kerneis S, Bogdanova A, Kraehenbuhl JP, et al. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Science. 1997; 277: 949-952.
206. Housley RM, Morris CF, Boyle W, et al. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest. 1994; 94: 1764-1777.
207. Kaoutzani P, Colgan SP, Cepek KL, et al. Reconstitution of cultured intestinal epithelial monolayers with a mucosal-derived T lymphocyte cell line. Modulation of epithelial phenotype dependent on lymphocyte-basolateral membrane apposition. J Clin Investig. 1994; 94: 788-796.
208. Barreau F, Madre C, Dusaillant M, et al. Nod2 regulates the host response towards microflora by modulating T-cell function and epithelial permeability in mouse Peyer's patches. Gut. 2009; 59: 207-217.
209. Pull SL, Doherty JM, Mills JC, et al. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci USA. 2005; 102: 99-104.